Dynamic covalent chemistry

Pivot Bio Raises $430 Million to Replace Synthetic Fertilizers in Agriculture

Retrieved on: 
Monday, July 19, 2021

Pivot Bio's clean nitrogen immediately decreases and permanently prevents synthetic nitrogen emissions from the environment, potentially avoiding approximately $200 billion of environmental impact.

Key Points: 
  • Pivot Bio's clean nitrogen immediately decreases and permanently prevents synthetic nitrogen emissions from the environment, potentially avoiding approximately $200 billion of environmental impact.
  • Pivot Bio's next stage of growth will focus on rapidly scaling its U.S. business and expanding into key international markets.
  • Pivot Bio has delivered the kind of win-win-win breakthrough DCVC is honored to back, and on which we are focused as a firm."
  • Pivot Bio PROVEN 40, the company's fourth commercial product in three years, enables farmers to replace up to 40 pounds per acre of synthetic nitrogen, almost double the performance of Pivot Bio's inaugural product.

Embark Welcomes HP Inc. Into Its Partner Development Program to Pioneer Commercial Self-Driving Freight Deployment

Retrieved on: 
Thursday, May 13, 2021

HP will play a critical role in testing self-driving truck technology in a real-world commercial setting, as well as providing data and feedback to Embark as it expands the PDP.

Key Points: 
  • HP will play a critical role in testing self-driving truck technology in a real-world commercial setting, as well as providing data and feedback to Embark as it expands the PDP.
  • "Embark is excited to work with HP to prepare their carrier network to operate Embark self-driving trucks.
  • Self-driving freight will inevitably help large shippers like HP bring additional speed and efficiency into their supply chains.
  • Embark was founded in 2016 and is backed by leading investors including Tiger Global, Sequoia Capital, DCVC, and Y Combinator.\n'

Unlearn.AI Announces Series A Extension with New Investment from Epic Ventures, Alumni Ventures Group, and Global Pharma Company Eisai

Retrieved on: 
Thursday, November 5, 2020

In April 2020, Unlearn announced Series A financing led by 8VC with participation from DCVC, DCVC Bio and Mubadala Capital Ventures.

Key Points: 
  • In April 2020, Unlearn announced Series A financing led by 8VC with participation from DCVC, DCVC Bio and Mubadala Capital Ventures.
  • The extension brings the Series A total to $15 million.
  • Unlearn has proven how generative AI-models trained on clinical data can be successfully utilized to create Digital Twins of patients for complex populations such as Alzheimers Disease.
  • Unlearn has developed a proprietary AI-model used to generate Digital Twins that are statistically indistinguishable from actual Alzheimers Disease patient data.